Please use this identifier to cite or link to this item:
Title: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization
Author: Crespo Guardo, Alberto
Gómez, Carmen Elena
Díaz Brito, Vicens
Pich, Judit
Arnaiz Gargallo, Juan Alberto
Perdiguero, Beatriz
García Arriaza, Juan
GonzÁlez, Núria
Sorzano, Carlos O. S.
Jiménez, Laura
Jiménez, José Luis
Muñoz Fernández, María Ángeles
Gatell, José M.
Alcamí, José
Esteban, Mariano
López Bernaldo de Quirós, Juan Carlos
García Alcaide, Felipe
Plana Prades, Montserrat
RISVAC02boost study
Keywords: VIH (Virus)
Vacunes antivíriques
Cèl·lules T
HIV (Viruses)
Viral vaccines
T cells
Issue Date: 24-Oct-2017
Publisher: Public Library of Science (PLoS)
Abstract: Background: We have previously shown that an HIV vaccine regimen including three doses of HIV-modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B) was safe and elicited moderate and durable (1 year) T-cell and antibody responses in 75% and 95% of HIV-negative volunteers (n = 24), respectively (RISVAC02 study). Here, we describe the long-term durability of vaccine-induced responses and the safety and immunogenicity of an additional MVA-B boost. Methods: 13 volunteers from the RISVAC02 trial were recruited to receive a fourth dose of MVA-B 4 years after the last immunization. End-points were safety, cellular and humoral immune responses to HIV-1 and vector antigens assessed by ELISPOT, intracellular cytokine staining (ICS) and ELISA performed before and 2, 4 and 12 weeks after receiving the boost. Results: Volunteers reported 64 adverse events (AEs), although none was a vaccine-related serious AE. After 4 years from the 1st dose of the vaccine, only 2 volunteers maintained low HIV-specific T-cell responses. After the late MVA-B boost, a modest increase in IFN-γ T-cell responses, mainly directed against Env, was detected by ELISPOT in 5/13 (38%) volunteers. ICS confirmed similar results with 45% of volunteers showing that CD4+ T-cell responses were mainly directed against Env, whereas CD8+ T cell-responses were similarly distributed against Env, Gag and GPN. In terms of antibody responses, 23.1% of the vaccinees had detectable Env-specific binding antibodies 4 years after the last MVA-B immunization with a mean titer of 96.5. The late MVA-B boost significantly improved both the response rate (92.3%) and the magnitude of the systemic binding antibodies to gp120 (mean titer of 11460). HIV-1 neutralizing antibodies were also enhanced and detected in 77% of volunteers. Moreover, MVA vector-specific T cell and antibody responses were boosted in 80% and 100% of volunteers respectively. Conclusions: One boost of MVA-B four years after receiving 3 doses of the same vaccine was safe, induced moderate increases in HIV-specific T cell responses in 38% of volunteers but significantly boosted the binding and neutralizing antibody responses to HIV-1 and to the MVA vector.
Note: Reproducció del document publicat a:
It is part of: PLoS One, 2017, vol. 12, num. 10, p. e0186602
Related resource:
ISSN: 1932-6203
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Fonaments Clínics)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
693519.pdf3.21 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons